Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan

Trial Profile

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cook Medical
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
    • 09 Nov 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
    • 30 Aug 2017 3 year results of the diabetic and in-stent restenosis subgroups presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top